Explore the latest in urologic cancer, including recent screening guidelines and advances in treatment of renal, bladder, and prostate cancers.
This dynamic cohort study evaluates the regional adoption of genomic testing for prostate cancer and the common trajectories of uptake shared by regions.
This study compares pathogenic variant detection accuracy in cancer-disposition genes of prostate cancer and melanoma cohort biopsy samples using deep learning vs standard genetic analysis methods.
This systematic review and meta-analysis examines 11 randomized clinical trials to see whether therapy with androgen receptor inhibitors (ARIs), such as enzalutamide, apalutamide, or darolutamide, is associated with an increased risk of falls and fractures in men with prostate cancer.
This JAMA Patient Page summarizes treatment options for early, invasive, and advanced bladder cancer.
This narrative review summarizes recent advances in the diagnosis and management of bladder cancer, including updates on its epidemiology, pathophysiology, molecular biology, and developments in surgical procedures and targeted treatments.
This diagnostic study evaluates whether the use of an artificial intelligence–based assistive tool is associated with improvements in the grading of prostate core needle biopsies among general pathologists compared with the majority opinion of subspecialists.
This case series study examines the prevalence of clonal hematopoiesis and its potential interference in prostate cancer cell-free DNA testing.
This cohort study estimates 10-year risk for disease progression, surgery, metastasis, and cause-specific and all-cause mortality among African American men with low-risk prostate cancer managed with active surveillance.
This narrative review discusses the use of postoperative radiotherapy in men with prostate cancer.
This study describes expanding neurologic phenotype, cancer associations, outcomes, and immunopathologic features of Kelch-like protein-11 encephalitis.
This cross-sectional survey study examines whether Black and White men with prostate cancer differ in their willingness to discuss clinical trials with their physicians, and if so, whether patient-level barriers are associated with racial differences.
This randomized clinical trial evaluates the efficacy and safety of nab-paclitaxel vs paclitaxel in patients with platinum-refractory metastatic urothelial cancer.
This case series characterizes the antitumor activity of platinum-based therapies in men with castration-resistant prostate cancer with or without DNA repair gene alterations.
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: